Results 211 to 220 of about 96,115 (285)

Developing a model to predict the early risk of hypertriglyceridemia based on inhibiting lipoprotein lipase (LPL): a translational study. [PDF]

open access: yesSci Rep, 2023
Hernandez-Baixauli J   +11 more
europepmc   +1 more source

Angiopoietin-Like 4 Mediates PPAR Delta Effect on Lipoprotein Lipase-Dependent Fatty Acid Uptake but Not on Beta-Oxidation in Myotubes

open access: gold, 2012
Marius R. Robciuc   +8 more
openalex   +2 more sources

In Vivo Therapeutic Potential of Biologically Synthesized Nanoparticles From Pine Needle Leaf Extract in Streptozotocin‐Induced Diabetic Rats

open access: yesBioMed Research International, Volume 2026, Issue 1, 2026.
Background Diabetes mellitus (DM) is one of the most widespread metabolic diseases characterized by increased blood glucose levels. According to the most recent research, the treatment of diabetes could be improved with the use of green‐synthesized nanoparticles due to their biocompatibility, efficient cellular uptake, and targeted therapy.
Nourhane A. Darwich   +5 more
wiley   +1 more source

Nonlinear and Age‐Specific Associations Between Atherogenic Index of Plasma and Differential Cardiovascular Risk Profiles in US Adults

open access: yesCardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Background The association between the atherogenic index of plasma (AIP) and different cardiovascular disease (CVD) outcomes remains insufficiently studied. Methods Data from 16,302 US adults in NHANES 2005–2020 were analyzed. CVD outcomes included congestive heart failure, coronary heart disease, angina, heart attack, and stroke.
Yuelin Hu   +5 more
wiley   +1 more source

Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR‐α: Mechanistic Insights and Therapeutic Implications

open access: yesCardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Hyperlipidemia remains a leading modifiable risk factor for cardiovascular morbidity and mortality. Statins are considered the cornerstone of treatment; however, their adverse effects and limited efficacy in certain patient populations necessitate exploration of novel therapeutic avenues. Epiafzelechin (EZN), a flavanol with established antioxidant and
Saud O. Alshammari   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy